Oncology Clinical Trial Finder
Breast Cancer

Completed • Phase NA • Stage 0, I, II, III, IV • Radiation • Post-Menopausal • Interventional

The following is imported from ClinicalTrials.gov:

Active Breathing Coordinator-based vs VisionRT-based Deep Inspiration Breath-hold for Radiation for Breast Cancer

Female patients treated with radiation for left-sided breast malignancy will undergo alternate fractions of Active Breathing Coordinator (ABC)-assisted and VisionRT-assisted Deep Inspiration Breath-Hold (DIBH).

Female patients treated with radiation for left-sided breast malignancy will undergo alternate fractions of ABC-assisted and VisionRT-assisted DIBH. Residual motion during breath-hold will be quantitatively assessed using MV fluoroscopy from the treatment beam itself (i.e., no additional radiation dose). The dosimetric impact of residual motion on organs at risk (heart and lung) will be assessed by applying rigid and/or deformable displacements to the planning CT images, computing the 3D dose map and comparing with the original planned dose map.

Breast Cancer

Study Design
Study type:


Estimated enrollment:

11 participant

Actual study start date:

February 20, 2016

Eligibility Criteria
Ages eligible for study:

18 - 999

Sexes eligible for study:


Arms and Intervention
  • Active Breathing Coordinator (ABC)

  • VisionRT

Inclusion criteria
  • Women with diagnosis of breast malignancy

  • Women whom requires left chest wall post-mastectomy radiation with or without bolus

  • Age ≥ 18 years.

  • Performance status ECOG </=3

  • Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately Ability to understand and the willingness to sign a written informed consent.

  • Patient must be able to maintain a 30 second breath hold.

  • Conventional chest wall radiation delivery dose of 50.4 Gy/ 28 fractions with or without a boost (boost will not be evaluated for endpoints)

Exclusion criteria
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

  • Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.

Trial Information at Site
Last Updated:
Trial Information
ClinicalTrial.gov ID:


Estimated Enrollment:


Last Updated:


Principal Investigator

Asal Rahimi, MD

Trial Sponsor

University of Texas Southwestern Medical Center

Study Location (1)

© 2024 Outcomes4Me Inc. All rights reserved.